The outcomes indicated that there were LTF expression variations in subgroups of tumor stage and N and T stages, SFXN3 in subgroups of tumor stage and M, N, T stage, and TFR2 in subgroups of M, T stage and tumor stage (Figs. 8A–8C). The gene discussed is SFXN3; the disease is neoplasm.